The FDA approves new Alzheimer’s drug

A new Alzheimer’s drug is a huge step forward in treatments.Officials and families impacted are even more hopeful for the days to come. The Food and Drug Administration approved the new Alzheimer’s drug just a few days ago. “Every step forward brings us a little bit closer to a world without Alzheimer’s,” said Beth Sulkowski, SC Alzheimer’s Association VP of communications.This drug is meant to slow the cognitive decline of the disease in people in the early stages. “This is a treatment that could potentially give them more good days and more time with their family. We’re talking months,” Sulkowski said.The Alzheimer’s Association and a family impacted by the disease say they’re so excited for this step forward. The new drug is Eli Lilly’s Kisunla. Though it’s not a cure, officials say it’s a breakthrough after decades of failed experimental treatments. “More independence, ability to do the things you love with the people you love, to make your own health care decisions. That is priceless when you’re facing and unrelenting and ultimately fatal disease,” Sulkowski said.Keith Young, a caregiver to his mother in the late stages of Alzheimer’s, is familiar with the disease. “She and I have been really closer because of this disease, and it’s something I have learned just in three years that life doesn’t prepare you for,” Young said. “My mom and I were very close when I grew up. She was more of the boss of the household, it wasn’t really my dad, my dad was the quiet one.”He also takes part in the Ride to End Alz fundraiser. When he got word of the new drug, he felt as if his dedication wasn’t for nothing.”Just hearing that FDA approved of a drug is exactly what I’m here for. This is why I have started committing my life to serving this cause this last year,” Young said. Though Young says it’s too late for his mom, he’s still working to help make an impact with this disease. “My goal right now is to somehow make her proud of me knowing that I’m out there serving other people, the next generation I call it,” Young said. This is now the second drug that’s proven to show a delay in the decline in Alzheimer’s patients.

GREENVILLE, S.C. —

A new Alzheimer’s drug is a huge step forward in treatments.

Officials and families impacted are even more hopeful for the days to come. The Food and Drug Administration approved the new Alzheimer’s drug just a few days ago.

“Every step forward brings us a little bit closer to a world without Alzheimer’s,” said Beth Sulkowski, SC Alzheimer’s Association VP of communications.

This drug is meant to slow the cognitive decline of the disease in people in the early stages.

“This is a treatment that could potentially give them more good days and more time with their family. We’re talking months,” Sulkowski said.

The Alzheimer’s Association and a family impacted by the disease say they’re so excited for this step forward.

The new drug is Eli Lilly’s Kisunla.

Though it’s not a cure, officials say it’s a breakthrough after decades of failed experimental treatments.

“More independence, ability to do the things you love with the people you love, to make your own health care decisions. That is priceless when you’re facing and unrelenting and ultimately fatal disease,” Sulkowski said.

Keith Young, a caregiver to his mother in the late stages of Alzheimer’s, is familiar with the disease.

“She and I have been really closer because of this disease, and it’s something I have learned just in three years that life doesn’t prepare you for,” Young said. “My mom and I were very close when I grew up. She was more of the boss of the household, it wasn’t really my dad, my dad was the quiet one.”

He also takes part in the Ride to End Alz fundraiser. When he got word of the new drug, he felt as if his dedication wasn’t for nothing.

“Just hearing that FDA approved of a drug is exactly what I’m here for. This is why I have started committing my life to serving this cause this last year,” Young said.

Though Young says it’s too late for his mom, he’s still working to help make an impact with this disease.

“My goal right now is to somehow make her proud of me knowing that I’m out there serving other people, the next generation I call it,” Young said.

This is now the second drug that’s proven to show a delay in the decline in Alzheimer’s patients.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source